NEW YORK and WALTHAM, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's participation and presentations by Marino Garcia, Chief Executive Officer, at the following healthcare investor conferences during the month of February:Guggenheim SMID Cap Biotech Conference - Fireside ...Full story available on Benzinga.com
Dianthus is a Massachusetts-based biotechnology company that develops and commercializes monoclonal antibody therapies for the treatment of autoimmune diseases.